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INTRODUCTION
Prader-Willi syndrome (PWS) is a contiguous gene syn-
drome that results from the non-expression of paternal alle-
les at the PWS locus; it is characterized clinically by uncon-
trollable hyperphagia, results in morbid obesity with the asso-
ciated somatic and psychological problems (1-3). Several stud-
ies have confirmed that plasma ghrelin levels are markedly
elevated in PWS adults (4, 5) and children (6, 7). Because
ghrelin acutely stimulates food intake and GH secretion in
rodents and humans, and because its chronic administration
to rodents causes obesity (8-12), it is possible that the increased
appetite in PWS might be due to the ghrelin level enhance-
ment. However, a direct anorexigenic effect of ghrelin, in its
physiologic range, has not been demonstrated in either ro-
dents or humans to date. The study of anorexigenic hormones
is of interest because appetite is also regulated by negative sig-
nals (13). Moreover, the response patterns of hormones to meals
have not been examined in detail in patients with PWS.
Peptide YY (PYY), an anorectic peptide, is secreted post-
prandially from the distal gastrointestinal tract. Moreover,
PYY3-36, the major form of circulating PYY, binds to the
hypothalamic NPY Y2 receptor (Y2-R) with a high affinity,
and has been shown to reduce food intake in rodents and hu-
mans (14-17). It has been reported that endogenous PYY
levels are low in obese subjects, suggesting that PYY defici-
ency may contribute to the pathogenesis of obesity (18). Cho-
lecystokinin (CCK) is an important feedback signal that con-
trols meal size; it is released from intestinal endocrine cells
both locally and into the plasma in response to the intralu-
minal presence of nutrient digestion products. CCK acts to
coordinate the digestive process in both an endocrine and a
paracrine/neurocrine manner by stimulating pancreatic and
gallbladder secretions, inhibiting gastric emptying, and by
modifying intestinal motility. In addition, CCK also plays a
major role in satiety (19). 
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Peptide YY, Cholecystokinin, Insulin and Ghrelin Response to Meal
did not Change, but Mean Serum Levels of Insulin is Reduced in
Children with Prader-Willi Syndrome
Prader-Willi syndrome (PWS) is a contiguous gene syndrome characterized by
uncontrollable eating or hyperphagia. Several studies have confirmed that plasma
ghrelin levels are markedly elevated in PWS adults and children. The study of ano-
rexigenic hormones is of interest because of their regulation of appetite by negative
signals. To study the pattern and response of the anorexigenic hormones such as
cholecystokinin (CCK) and peptide YY (PYY) to a meal in PWS, we measured the
plasma CCK, PYY, ghrelin and serum insulin levels in PWS patients (n=4) and in
controls (n=4) hourly for a day, and analyzed hormone levels and hormonal respon-
ses to meals. Repeated measures of ANOVA of hormone levels demonstrated that
only insulin levels decreased (p=0.013) and CCK (p=0.005) and ghrelin (p=0.0007)
increased in PWS over 24 hr. However, no significant group x time interactions
(ghrelin: p=0.89, CCK: p=0.93, PYY: p=0.68 and insulin: p=0.85) were observed;
in addition, there were no differences in an assessment of a three-hour area under
the curve after breakfast. These results suggest that the response pattern of hor-
mones to meals in PWS patients parallels that of normal controls. In addition, the
decrease of insulin levels over 24 hr, in spite of obesity and elevated ghrelin levels,
suggests that the baseline insulin level, not the insulin response to meals, may be
abnormal in patients with PWS.
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Insulin is a physiological and dynamic modulator of plas-
ma ghrelin and glucose levels, and possibly mediates their
effect on nutritional status (10). Moreover, it has been reported
that insulin has an inhibitory effect on ghrelin secretion that
is independent of plasma glucose levels, although these mole-
cules may have additional effects (20, 21).
In this study, the 24-hr PYY, CCK, insulin and ghrelin
profiles of children with PWS (n=4) were compared with
those of age, gender, and BMI matched controls (n=4); the
responses of these hormones to meals were evaluated.
MATERIALS AND METHODS
Subjects
Four PWS patients (n=4, mean body mass index (BMI)=
39±5.9 kg/m2, mean fat %=58.4±5.9%) and four age,
gender and BMI matched controls (n=4, mean BMI=39±
5.7 kg/m2, mean fat %=51.2±3.7%) were enrolled in the
present study. Patients with diabetes mellitus (fasting plas-
ma glucose >126 mg/dL with a 2-hr post-prandial glucose
value of >200 mg/dL) were excluded. The patient clinical
characteristics are detailed in Table 1. Informed consent was
obtained from all participants or parents, as appropriate. The
study design was reviewed and approved by the Samsung
Medical Center Institutional Review Board.
For controls, several middle and high schools located in
the southern part of Seoul were recruited. We explained the
purpose of the study to teachers, and a written study protocol
was sent to all parents. Of 23 volunteers, four controls were
selected on the basis of age, sex, and BMI. All study subjects
were males. We explained the purpose and methods of the
study, and informed consent was obtained from all parents.
Experimental design
For this 24-hr study, all subjects were admitted to the Pedi-
atric Ward at the Samsung Medical Center; they ate a stan-
dard hospital diet [meals served at 7:30 AM, 12:00 PM, and
18:00 PM, total calories 2100 calories consisting of 60%
carbohydrate (310 g), 20% protein (100 g) and 20% fat (50
g)] and were allowed to sleep (lights-off) between 11:00 PM
and 7:00 AM. During the remainder of the day, lights were
on and sleeping and snacking were not allowed. Blood was
drawn to measure hormones through an indwelling venous
cannula and was collected in EDTA and SST tubes every hour
for 24 hr without the addition of aprotinin. After taking a
baseline sample, which was collected at 7:00 AM before break-
fast, a total of 23 additional samples were collected at hourly
intervals from each patient. Samples were stored at 4℃ dur-
ing the collection period, centrifuged for plasma within two
hours of collection, and stored at -70℃until assayed. 
Hormonal assay
Plasma immunoreactive ghrelin was measured in duplicate
using a commercial ELISA kit (Phoenix Pharmaceuticals,
Belmont, CA); the inter- and intra-assay coefficients of vari-
ance were <10%. The lower and upper detection limits for
this assay were 0.75 ng/mL and 100 ng/mL.
Plasma immunoreactive PYY was measured in duplicate
using a commercial ELISA kit (Peninsula Laboratories, Inc.);
inter- and intra-assay coefficients of variance were <10%, and
the assay detection range was 0-25 ng/mL. The antibody
against human PYY(3-36) exhibited 100% cross-reactivity with
full-length PYY.
CCK was measured by radioimmunoassay using synthetic
CCK8 (sulphated) [Bachem] as a standard, antibody code
R7 (3) (final dilution 1:100,000); the intra-assay CVs were
8.2 and 6.6% at 5 ng/L and 15 ng/L, respectively, and the
inter-assay CVs were 13.3 and 11.5% at 5 ng/L and 15 ng/L,
respectively, with a lower detection limit of 1.5 ng/L.
Serum insulin was measured using a commercially avail-
able immunoradiometric assay kit (BioSource Europe S.A.)
with a detection limit of 1  IU/mL and intra- and inter-assay
coefficients of variation of <10%. 
Statistical analysis 
All values are expressed as means±SE. Repeated measures
of ANOVA was used to compare the 24-hr hormone profiles
of the two groups. Increments or decrements in areas under
the curve (AUC) for each hormone profile (from 7:00 AM to
10:00 AM) were calculated using the trapezoid method after
subtracting the basal AUC from the calculated AUC, and
Mann-Whitney test was used to compare them between the
two groups. p values of <0.05 were regarded as statistically
significant. All statistical analyses were performed using SAS
Percent 
body fat 
(%)
Subject Age (yr)
% of the
ideal wt
BMI
(kg/m
2)
BMI
per-
centile
Geno-
type
P1 11 131 24 >95 46.3 Deletion
P2 16 248 49 >95 69.0 Deletion
P3 16 255 48 >95 67.9 Deletion
P4 11 204 35 >95 50.5 Deletion
Mean±SE 13.5± 209.5± 39± 58.4±
1.4 28.5 5.9 5.9
C1 11 137 25 >95 41.0
C2 17 250 51 >95 58.0
C3 17 250 45 >95 55.0
C4 12 195 35 >95 50.9
Mean±SE 14.25± 208.0± 39± 51.2±
1.6 27.0 5.7 3.7
Table 1. Characteristics of the study subjects (all males, P1-4:
PWS, C1-4: control) 
BMI, body mass index.438 K.H. Paik, D.-K. Jin, K.H. Lee, et al.
version 8.2 (SAS Corporation, Cary, NC).
RESULTS
The characteristics of the study subjects are detailed in
Table 1. The PWS and control groups did not differ signifi-
cantly with respect to age, % of ideal body weight, BMI,
BMI percentile, or in terms of percent body fat as determined
by a dual energy absorptiometry (DEXA). 
Twenty-four hour PYY levels are illustrated in Fig. 1. Re-
peated measures of ANOVA of PYY levels showed no sig-
nificant difference between the two groups (p=0.06). There
was no significant group×time interaction (p=0.68). There-
fore, the PYY levels were similar in the two groups over 24
hr; their PYY responses to meals were also similar, and in-
creases in the AUC of PYY after breakfast (7 AM-10 AM)
were not significantly different in comparisons between PWS
(0.14±0.14 ng/mL×3 hr) and controls (0.008±0.18 ng/
mL×3 hr, p=0.31) (Table 2).
Fig. 2 shows the 24 hr CCK profiles. Repeated measures
of ANOVA of the CCK profiles identified a significant dif-
ference between the two groups (p=0.0051) but without a
significant group x time interaction (p=0.9311). These results
indicate that the mean CCK levels were elevated over 24 hr,
but that the CCK response to meals was not different in com-
parisons between the two groups. In addition, increments
in AUC of CCK after breakfast (7 AM-10 AM) were not
significantly different (Table 2). We interpreted these results
to mean that although there was an elevation in the mean
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Fig. 1. 24-hr mean plasma peptide YY (PYY) profiles (mean±SE)
in Prader-Willi syndrome (PWS) (n=4) and sex- and age- matched
controls (n=4). Hourly PYY values (0.46±0.01 ng/mL) were com-
pared with those of controls 1-4 (0.48±0.01 ng/mL). PYY levels
were not different over 24 hr, and PYY responses to meals were
similar in the PWS and control groups (p=0.68). Arrows indicate
meal times. 
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Fig. 2. 24-hr mean plasma cholecystokinin (CCK) profiles (mean±
SE) in Prader-Willi syndrome (PWS) (n=4) and in sex- and age-
matched controls (n=4). The hourly CCK values of PWS patients
(7.21±0.68 pg/mL) were compared with those of controls (4.16
±0.35 pg/mL).
These results indicate that mean CCK levels were elevated over
24 hr (p=0.0051), but the CCK response to meals was similar in
the two groups (p=0.9311).
PWS Controls p-value
PYY
Incremental AUC  0.14±0.07 0.008±0.09 0.312
(ng/mL×3 hr)
CCK
Incremental AUC  9.0±2.61 8.6±5.89 1.0
(pg/mL×3 hr)
Insulin
Incremental AUC  128.85±98.87 55.55±68.59 0.194
( IU/mL×3 hr)
Ghrelin
Decremental AUC 0.026±2.30 -0.41±0.79 0.665
(ng/mL×3 hr)
Table 2. Comparison of ghrelin, PYY, CCK and insulin responses
to breakfast (mean±S.E) in PWS patients and controls (basal
time 7 AM)
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Fig. 3. 24-hr mean plasma insulin profiles (mean±SE) in Prader-
Willi syndrome (PWS) (n=4) and in sex- and age- matched con-
trols (n=4). Hourly insulin values were compared between the
two groups. Plasma insulin levels in the PWS group were lower
(mean 29.19±3.23 IU/mL) than in controls (mean 43.12±3.53
IU/mL) throughout the 24-hr insulin monitoring period (p=0.01).
However, insulin response to meals were similar in the two groups
(p=0.85). 
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CCK levels over 24 hr, the CCK response to meals was not
significantly different in comparisons between the two groups.
Twenty-four hour insulin levels are shown in Fig. 3. The
repeated measures of ANOVA of the insulin levels demon-
strated a significant difference between the two groups (p=
0.013), but there was no significant difference between the
two in terms of group×time interaction (p=0.85). These
data show that insulin responses to meals were similar in the
two groups; however, the levels of insulin over 24 hr were
relatively lower in the PWS patients. Increments in the AUC
of insulin after breakfast (7 AM-10 AM) were similar in the
two groups (Table 2).
In addition, we measured the 24-hr ghrelin levels; they
were higher in PWS than in controls (p=0.0007). However,
no significant difference was found in terms of the group×
time interaction (p=0.89) or between decrements in the AUC
of ghrelin after breakfast (7 AM-10 AM, Table 2). These
results show that ghrelin suppression after meals was simi-
lar in the two groups.
DISCUSSION
Our results show that the response pattern of CCK, PYY,
insulin and ghrelin to meals in PWS patients was not differ-
ent from that of controls. In addition, we demonstrated that
only insulin levels decreased (p=0.013), while the other hor-
mone levels either increased or did not change. Therefore,
reduced mean levels of insulin as well as elevated mean levels
of ghrelin were the major results in the PWS patients.
It has been repeatedly reported that plasma ghrelin is ele-
vated in both adults and children with PWS, which is in
contrast to the ghrelin levels found in other causes of obesi-
ty, where ghrelin levels have been shown to be decreased (4,
22). Based on rodent and human studies elevated ghrelin
levels might be associated with an increase in appetite, (8-
11) although the direct orexigenic effects of ghrelin, in its
physiologic range, have not been demonstrated in rodents
or humans. However, studies showing an increased appetite
in PWS are insufficient without an understanding of the
effects of anorexigenic hormones; this is because appetite is
also negatively influenced by several hormones. Thus, if ano-
rexigenic hormones are reduced, the increased appetite asso-
ciated with PWS could be explained by another mechanism.
However, these hormones fluctuate widely after meals. Thus,
a single determination of hormone levels in a given day is
not adequate for understanding appetite-related hormonal
changes in PWS.
CCK levels in PWS have been reported several times. One
report emphasized a significant increase in serum CCK levels
during meals in PWS patients, indicating that a failure of
peripheral CCK release in response to food intake does not
explain the impaired satiety response in PWS (23); however,
two additional reports did not find CCK elevation in PWS
(24, 25). In our study, hourly CCK monitoring data suggest-
ed that CCK secretion in response to a meal was similar in
PWS patients and in controls. However, we did note an ele-
vation in serum CCK levels in PWS. These results showed
that in PWS the failure of peripheral CCK release, in response
to food intake, cannot explain the impaired satiety response.
Our data suggest that anorexigenic hormones may potentially
influence the gastrointestinal tract peripherally and appetite
centrally. Recently, we reported that gastric emptying in PWS
was not elevated, and that actually it tended to be delayed,
despite the presence of higher ghrelin levels, which generally
promote gastric emptying (26). CCK may potentially delay
gastric emptying; however, further evidence is needed to con-
firm this.
Batterham et al. reported that the gut hormone fragment
peptide YY3-36 reduces appetite, food intake, and plasma ghre-
lin levels when infused into both normal weight and obese
subjects (18, 27). Endogenous PYY levels were depressed in
obese subjects, and the fasting PYY levels were found to cor-
relate negatively with BMI (26).
Moreover, plasma PYY levels in PWS were reported to be
lower than those of similarly aged individuals without PWS;
however, other reports did not confirm this (28, 29). In the
present study, we observed that these hormones fluctuate
widely according to meal times; however, we found no sig-
nificant difference between the PWS patients and controls in
regard to the PYY levels. Our data shows that PYY response
to meals and basal PYY levels are similar in PWS patients
and normal controls; this suggests that a failure to secrete
PYY in response to food is not an explanation for the impaired
satiety response observed in PWS. Our data are consistent with
the recent observation that there is no deficiency of the anorex-
igenic intestinal hormone PYY in PWS (29).
As for insulin, we observed lower insulin levels in PWS
than in controls over the 24-hr monitoring period. This find-
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Fig. 4. 24 hr mean plasma ghrelin profiles (mean±SE) in Prader-
Willi syndrome (n=4) and in sex-age matched controls (n=4). 
Plasma ghrelin levels in the PWS group were higher (mean 5.61±
0.5  g/mL) than in controls (mean 2.08±0.13 ng/mL) (p<0.001)
throughout the 24 hr monitoring period, but ghrelin suppression
after meals was similar in the two groups (p=0.89).440 K.H. Paik, D.-K. Jin, K.H. Lee, et al.
ing is consistent with previous reports, which found that
insulin resistance is lower in PWS subjects, and that insulin
sensitivity is higher than in obese controls (30-33). Unfor-
tunately, we did not measure the 24-hr serum glucose pro-
file, which is a limitation of this study. However, because fast-
ing and post-prandial two-hour glucose levels were normal
in all subjects and standard hospital diet was served to all of
them, this limitation may not have influenced our results.
Recently, it was reported that deficits in insulin and glu-
cagons, during fetal and postnatal life, are prominent find-
ings in the TgPWS deletion mouse model, and that a pan-
creatic defect may be the primary lesion (34). Consistent with
these findings is the presence of type 2 diabetes in PWS, which
may partly result from the lowered insulin levels observed
compared to the expected levels for the degree of increased
body mass index (35-37). In addition, this model showed
that increased plasma ghrelin levels occurred in the postna-
tal TgPWS mice and appeared to begin at the onset of severe
hypoglycemia; this suggests that the hyperghrelinemia, ob-
served in PWS, might be a physiological adaptive mecha-
nism of increased eating in response to hypoglycemia (32).
However, insulin alone is insufficient to lower the ghrelin
levels to control levels, i.e., the ghrelin baseline in PWS was
almost always higher than in controls. Therefore, elevated
ghrelin levels may be explained by at least two mechanisms,
i.e., by insufficient insulin levels and by an adaptive response
to hypoglycemia during the postnatal period. However, the
precise mechanism of hyperghrelinemia in PWS remains to
be determined.
In conclusion, our results suggest that the response pattern
of hormones to meals in PWS patients parallels that of nor-
mal controls. In addition, a decrease of the insulin level over
24 hr, in spite of obesity and elevated ghrelin levels, suggests
that the baseline insulin level, not the insulin response to
meals, may be the important abnormality in PWS.
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